Key result
Switching to lower-liability antipsychotics reduces cholesterol and triglycerides but increases treatment discontinuation.
Why the study?
Does antipsychotic switching, dose reduction, or discontinuation reverse antipsychotic-induced dyslipidaemia (total cholesterol, LDL, HDL, and triglycerides) in adults?
Does antipsychotic switching, dose reduction, or discontinuation reverse antipsychotic-induced dyslipidaemia (total cholesterol, LDL, HDL, and triglycerides) in adults?
Answers are grounded in this paper and cite their sources.
Antipsychotic-induced dyslipidaemia is partly reversible—most effectively and rapidly by switching to a lower-liability agent—but any regimen modification must be weighed against increased risks of treatment discontinuation and psychiatric relapse.
People with schizophrenia have a markedly shorter life expectancy than the general population, largely because of cardiovascular disease, and antipsychotic medication contributes to their dyslipidaemia.Whether antipsychotic-induced lipid changes are reversible is clinically important, but the evidence has not been brought together across management strategies.This narrative review examined randomised controlled trials and cohort studies published between 2000 and 2026 that evaluated switching, dose reduction or discontinuation in adults.Total cholesterol was the main outcome, and low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides were also examined.PubMed and Embase were searched, and 54 studies were included.Switching from olanzapine, quetiapine, risperidone or clozapine to a lower-liability agent such as aripiprazole, ziprasidone, lurasidone, cariprazine or amisulpride generally reduced triglycerides and total cholesterol.Changes were evident within three to eight weeks and were sustained for up to a year.Benefits were greatest after leaving olanzapine and in patients with higher baseline lipids and were absent when switching between agents of similar liability.In randomised trials, however, switching increased discontinuation of the new treatment.Dose reduction was associated with modest falls in total, LDL and non-HDL cholesterol but not triglycerides, with a trade-off against relapse.Discontinuation improved lipids without fully normalising them and substantially increased relapse.Where switching is not possible, statins, metformin and glucagon-like peptide-1 receptor agonists improve lipids.The evidence is limited by open-label designs, short follow-up and industry funding.Antipsychotic-induced dyslipidaemia is partly reversible, and switching has the strongest evidence.Any change should be individualised, closely monitored and combined with lipid-lowering and lifestyle interventions.
No takes yet. Share an insight, caveat, or question.
Adekanmbi et al. (2026) conducted a review in Antipsychotic-induced dyslipidaemia in adults. Antipsychotic switching to a lower-liability agent, dose reduction, or discontinuation vs. Continuing current antipsychotic therapy or switching between agents of similar metabolic liability was evaluated on Change in total cholesterol. Switching from high-liability antipsychotics to lower-liability agents reduced total cholesterol and triglycerides within 3 to 8 weeks, though it increased treatment discontinuation in RCTs.
Synapse has enriched 10 related papers. Consider them for comparative context: